Selegiline Mechanism of Action: How It Inhibits MAO-B

Selegiline works primarily by permanently disabling monoamine oxidase type B (MAO-B), the enzyme responsible for breaking down dopamine in the brain. By knocking out this enzyme, selegiline allows dopamine to linger longer at nerve synapses, which is why it has been used for decades in Parkinson’s disease and, more recently, in depression. But MAO-B inhibition is just the headline act; selegiline also blocks dopamine reuptake, boosts the production of protective brain growth factors, ramps up antioxidant defenses, and gets metabolized into some surprising byproducts. The drug’s full pharmacological profile is considerably more layered than a single enzyme target would suggest.

How Selegiline Permanently Disables MAO-B

Selegiline belongs to a class of drugs called propargylamine inhibitors. When it enters the brain and reaches an MAO-B enzyme molecule, it forms a permanent covalent bond with the enzyme’s flavin adenine dinucleotide (FAD) cofactor, the part of the enzyme that normally does the chemical work of breaking down dopamine.¹ Once that bond forms, the enzyme is dead. It cannot recover. The body has to manufacture entirely new MAO-B molecules to replace the ones selegiline has knocked out, a process that takes roughly two weeks.

Computational studies have mapped how this happens at the molecular level. The inactivation proceeds in three steps: in the rate-limiting first step, the FAD cofactor uses its nitrogen atom to pull a hydrogen away from selegiline’s chemical structure, which ultimately produces a stable drug-enzyme complex that matches what researchers see in crystal structures of the inhibited enzyme.² The irreversibility is a feature, not a bug: it means that even after selegiline itself has been cleared from the bloodstream, the enzyme remains inhibited until the body builds fresh copies.

Why Blocking MAO-B Raises Dopamine Levels

In the human brain, dopamine is broken down mainly by MAO-B rather than by MAO-A (which preferentially handles serotonin and norepinephrine in the gut and liver). When selegiline disables MAO-B, the brain’s dopamine levels rise because less dopamine is being chewed up.³ At the standard clinical dose of 10 mg per day taken orally, selegiline selectively inhibits MAO-B while leaving MAO-A largely intact, which matters because MAO-A inhibition in the gut is what creates the infamous “cheese effect,” a dangerous spike in blood pressure triggered by tyramine-rich foods.⁴

This selectivity is dose-dependent, though. At higher oral doses, selegiline starts to inhibit MAO-A too, erasing the safety margin for tyramine and changing the drug’s risk profile. That dose ceiling is one reason selegiline was originally approved only at 10 mg per day for Parkinson’s disease: high enough to meaningfully preserve dopamine, low enough to avoid broadly suppressing monoamine oxidase throughout the body.

Effects Beyond Enzyme Inhibition

If selegiline only blocked MAO-B, it would be a simpler drug to explain. But research over the past several decades has uncovered additional pharmacological actions that contribute to its clinical effects, and some of these may matter as much as the enzyme inhibition itself.

Selegiline inhibits the reuptake of dopamine from the synaptic cleft back into the presynaptic neuron.⁵ It also increases the turnover of dopamine and enhances its release, producing what has been described as an amphetamine-like effect on dopaminergic signaling.⁶ This is not a coincidence: selegiline is metabolized in the liver into l-methamphetamine and l-amphetamine (more on that shortly), and some of these downstream actions on dopamine release and reuptake are thought to come partly from the drug’s metabolites.

Additionally, selegiline inhibits norepinephrine uptake.⁷ This combined effect on dopamine and norepinephrine may help explain why selegiline has shown utility beyond Parkinson’s disease, particularly in depression, where multiple monoamine systems tend to be involved.

Neuroprotection and Antioxidant Defense

One of the more intriguing aspects of selegiline’s pharmacology is its apparent ability to protect neurons from damage through mechanisms that go beyond simply keeping dopamine levels up. Researchers have identified several overlapping neuroprotective actions.

In rat studies, selegiline significantly increased the activity of catalase and superoxide dismutase (SOD2) in the striatum, the brain region most affected in Parkinson’s disease, and also raised glutathione levels.⁸ These are all components of the brain’s built-in defense system against oxidative stress, the kind of cellular damage caused by reactive oxygen species that accumulate with aging and are thought to accelerate the death of dopamine-producing neurons. The antioxidant effects were region-specific, appearing in the striatum but not in the cortex or hippocampus, suggesting the drug preferentially protects the areas most vulnerable in Parkinson’s.

Selegiline and its close pharmacological relative rasagiline have also been shown to regulate the mitochondrial cell-death pathway, maintain mitochondrial function, increase expression of anti-apoptotic proteins like Bcl-2, and suppress the aggregation of alpha-synuclein, the protein that clumps together in the brains of people with Parkinson’s.⁹ Whether these effects are large enough to meaningfully slow disease progression in humans remains a more complicated question, but the breadth of the neuroprotective profile has kept researchers interested for decades.

Stimulating Brain Growth Factors

Separately from its antioxidant actions, selegiline upregulates the production of neurotrophic factors, proteins that support the survival, growth, and maintenance of neurons. In cultured mouse brain cells, treatment with selegiline boosted production of nerve growth factor (NGF) by about 26-fold, glial cell line-derived neurotrophic factor (GDNF) by about 4-fold, and brain-derived neurotrophic factor (BDNF) by about 1.7-fold.¹⁰ Desmethylselegiline, one of selegiline’s metabolites, produced similar effects, suggesting the drug’s neuroprotective benefits may continue even after the parent compound has been broken down.

These findings have been replicated in animal models of neurological injury. In a rat spinal cord injury model, selegiline administration improved locomotor function and increased the expression of BDNF, GDNF, and other neurotrophins.¹¹ Gene expression studies in human glioblastoma cells have shown that selegiline’s enhancement of neurotrophic factor and Bcl-2 gene expression involves signaling pathways that go beyond simple MAO-B inhibition.¹² In other words, selegiline seems to be doing something in these cells that is not entirely explained by its enzyme-blocking activity, a theme that keeps recurring across its pharmacology.

Metabolism and Its Unusual Byproducts

When you swallow an oral selegiline tablet, the liver gets to work breaking it down before most of the drug reaches the brain. The primary metabolic products are desmethylselegiline and l-methamphetamine, produced mainly by the liver enzyme CYP2B6 with contributions from CYP3A4 and CYP2A6.¹³ L-methamphetamine is further metabolized to l-amphetamine. Yes, these are the same chemical structures as the more familiar d-methamphetamine and d-amphetamine, but the “l” (levorotatory) forms are far weaker stimulants than their “d” (dextrorotatory) mirror images. L-methamphetamine has roughly one-tenth or less the central stimulant potency of d-methamphetamine, so while the metabolites contribute to selegiline’s dopamine-releasing effects, they do not produce the kind of euphoria or compulsive use associated with illicit methamphetamine.

That said, these metabolites are not pharmacologically inert. They can cause insomnia and restlessness in some patients, which is why selegiline is typically dosed in the morning or in a split morning-and-midday regimen to avoid sleep disruption. The metabolites also explain why selegiline can produce a positive result on certain urine drug screens for amphetamines, a practical headache for patients who undergo workplace drug testing.

How the Delivery Route Changes the Drug’s Behavior

Oral selegiline has a problem: the liver metabolizes so much of it before it reaches the brain that you end up with a lot of those methamphetamine and amphetamine metabolites relative to the amount of intact selegiline getting to its target. The selegiline transdermal system (marketed as EMSAM) was developed specifically to get around this. By delivering the drug through a skin patch, it bypasses the liver’s first-pass metabolism, putting more selegiline directly into the bloodstream and ultimately into the brain.¹⁴

This matters for two reasons. First, the lower metabolite burden means fewer stimulant-type side effects. Second, and more important clinically, the transdermal route allows the drug to inhibit both MAO-A and MAO-B in the brain (producing antidepressant effects) while minimally affecting MAO-A in the gastrointestinal tract and liver.¹⁵ With gut MAO-A still largely functional, the risk of a tyramine-triggered hypertensive crisis drops substantially. At the lowest patch dose (6 mg/24 hours), the FDA allows use without the dietary restrictions that normally accompany MAO inhibitor therapy. Higher patch doses still require tyramine avoidance, but the overall safety margin is significantly wider than it would be with an equivalent systemic MAO-A inhibition from oral dosing.

Selegiline in Parkinson’s Disease

In Parkinson’s disease, selegiline is used both as early monotherapy and as an add-on to levodopa. As monotherapy, it provides a modest symptomatic benefit by preserving whatever dopamine the surviving neurons are still producing. A long-term Finnish study found that patients on selegiline needed progressively lower doses of levodopa compared to those on placebo; after five years, the placebo group required about 19% more levodopa. There was also a trend toward delayed onset of wearing-off fluctuations, with a hazard ratio of 0.55, though this did not quite reach conventional statistical significance.¹⁶

As adjunctive therapy in patients already experiencing motor fluctuations on levodopa, selegiline reduces daily “off” time, the periods when the medication effect wears off and Parkinson’s symptoms return. In a randomized trial of an orally disintegrating formulation, patients on selegiline gained roughly 2.2 fewer hours of off time per day compared to about 0.6 hours in the placebo group, and their dyskinesia-free on time increased by 1.8 hours at 12 weeks.¹⁷ Earlier work combining selegiline with controlled-release levodopa showed a mean reduction of about 20% in the required levodopa dose.¹⁸

Selegiline’s value in Parkinson’s therefore comes from two directions at once: it boosts dopamine levels on its own and it stretches the effect of levodopa, which remains the single most effective drug for the disease’s motor symptoms.

The Transdermal Patch in Depression

The transdermal formulation opened a new clinical use entirely. Traditional oral MAO inhibitors are effective antidepressants but have been sidelined for decades because of the dietary restrictions and drug interaction risks they carry. By delivering selegiline through the skin and selectively inhibiting both MAO-A and MAO-B in the brain without substantially knocking out gut MAO-A, the patch offered a way to revive MAO inhibitor therapy in a safer form.¹⁹ EMSAM was approved by the FDA in 2006 for major depressive disorder, making it the first transdermal treatment for depression and the first MAO inhibitor approved in the United States in over two decades.

The antidepressant mechanism is fundamentally different from the Parkinson’s mechanism in emphasis. In Parkinson’s, the goal is selective MAO-B inhibition to boost dopamine in the nigrostriatal pathway. In depression, the goal is broader monoamine preservation: by inhibiting both MAO-A and MAO-B in the brain, the patch raises serotonin and norepinephrine (MAO-A substrates) as well as dopamine (an MAO-B substrate), addressing the multiple neurotransmitter deficiencies implicated in depressive disorders.

How Selegiline Compares to Newer MAO-B Inhibitors

Selegiline was the first selective MAO-B inhibitor, synthesized by Joseph Knoll in the 1960s and eventually registered in more than 60 countries.²⁰ Two other MAO-B inhibitors are now in clinical use: rasagiline and safinamide. Each differs from selegiline in ways that matter clinically.

Like selegiline, rasagiline is an irreversible inhibitor that forms a covalent bond at the MAO-B active site.²¹ However, rasagiline is not metabolized into amphetamine derivatives. Its primary metabolite is aminoindan, which avoids the stimulant-type side effects and drug-screen complications associated with selegiline’s metabolites. For patients who experience insomnia or anxiety on selegiline, rasagiline is often a practical alternative.

Safinamide takes a different approach altogether. It is a reversible MAO-B inhibitor, meaning its binding to the enzyme is temporary rather than permanent. This gives it a shorter duration of action and makes it easier to wash out of the system if needed. Safinamide also inhibits voltage-sensitive sodium channels and glutamate release, giving it a dual mechanism that addresses both dopaminergic and non-dopaminergic pathways.²² None of the three has been shown definitively superior in head-to-head trials for motor symptom control, so the choice among them often comes down to side-effect profile, metabolite concerns, and individual patient tolerance.

Safety and Drug Interactions

The most clinically dangerous interaction with selegiline involves serotonergic drugs, particularly selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants. Because selegiline inhibits MAO-B and, at higher doses or transdermal delivery, MAO-A, combining it with drugs that increase serotonin can push serotonin levels dangerously high, triggering serotonin syndrome: a potentially life-threatening condition involving agitation, muscle rigidity, rapid heart rate, and hyperthermia. Selegiline’s prescribing information was revised to reflect this risk, and concurrent use with SSRIs is generally considered a contraindication.²³

The tyramine interaction is the other well-known risk. MAO-A in the gut wall normally breaks down tyramine before it reaches the bloodstream. If gut MAO-A is inhibited (which happens at higher oral selegiline doses or with non-selective MAO inhibitors), tyramine from aged cheeses, cured meats, fermented foods, and draft beers can flood the system and cause a hypertensive crisis. At the standard Parkinson’s dose of 10 mg per day orally, this risk is low because gut MAO-A remains mostly intact. With the transdermal patch at its lowest dose, the risk is similarly low. But the risk is real and escalates at higher doses or when patients are also taking other drugs that affect monoamine metabolism. Meperidine (a narcotic pain medication) is another specific drug that should be avoided due to the risk of severe reactions.

The Longevity Question

One of the more unusual chapters in selegiline’s history involves its investigation as a lifespan-extending drug. Starting in the late 1980s, animal researchers reported that selegiline (then commonly called l-deprenyl) extended life in rats, mice, hamsters, and dogs. A positive effect on longevity was demonstrated across all four species, though the size of the effect varied considerably.²⁴ The proposed mechanism centered on the drug’s ability to raise antioxidant enzyme activity in the brain, particularly superoxide dismutase and catalase, thereby reducing oxidative damage to the aging dopaminergic system.

Not every study reproduced the effect. A long-term study in male Fischer 344 rats, a commonly used aging model, found no clear longevity benefit from chronic selegiline treatment.²⁵ A recent meta-analysis pooling 22 longevity experiments across mammalian species attempted to resolve these conflicting results, and the broader body of evidence suggests that multiple mechanisms may be at work: MAO-B inhibition counteracting age-related increases in the enzyme’s activity, antioxidant enzyme upregulation in both the brain and peripheral tissues, immunomodulatory effects, and what researchers call catecholaminergic activity enhancer (CAE) effects, where even very low doses of selegiline that do not meaningfully inhibit MAO-B can still enhance the activity of dopamine-producing neurons.²⁶

Whether any of this translates to human longevity is unknown. No controlled lifespan studies in humans have been conducted with selegiline, and it would be nearly impossible to design one. The longevity data has fueled interest in selegiline within the anti-aging and biohacking communities, where some individuals take low doses off-label in the hope of slowing brain aging. The scientific case for this remains speculative, resting on animal data with inconsistent results and multiple candidate mechanisms, none of which has been conclusively identified as the primary driver of the observed lifespan effects in animals.

The Catecholaminergic Activity Enhancer Effect

One of the more recent and less well-known mechanisms attributed to selegiline is its role as a catecholaminergic activity enhancer, or CAE. Joseph Knoll, the scientist who originally synthesized selegiline, proposed late in his career that the drug could boost the firing and output of catecholamine neurons (those using dopamine and norepinephrine) at doses far too low to meaningfully block MAO-B. In a study testing this idea, rats given extremely low doses of selegiline (0.001 mg/kg and 0.1 mg/kg) showed lifespan extension even though MAO-B inhibition was negligible at those doses. A more potent synthetic CAE compound called BPAP produced an even stronger longevity effect.²⁷

If confirmed by further research, the CAE mechanism would mean that selegiline’s pharmacological story is even more complex than currently understood: at clinical doses, it simultaneously inhibits MAO-B, blocks dopamine reuptake, enhances dopamine release, upregulates antioxidant enzymes, stimulates neurotrophic factor production, and enhances catecholamine neuron activity through a pathway that operates independently of enzyme inhibition. Few drugs in common clinical use have this many distinct pharmacological actions attributed to them, and sorting out which of these actually matter for patients at real-world doses remains an active area of investigation.